Reconstituted depolarization-induced Ca2+ release platform for skeletal muscle disease mutation validation and drug discovery
T. Murayama, N. Kurebayashi, T. Numaga-Tomita, T. Kobayashi, S. Okazaki, K. Yamashiro, T. Nakada, S. Mori, R. Ishida, H. Kagechika, M. Yamada, T. Sakurai
The paper establishes a reconstituted DICR platform in HEK293 cells to validate skeletal muscle disease mutations and test drug candidates.
bioRxiv · Jun 29, 2022Physiology